EGFR-mutated NSCLC: A roadmap to treatment sequences.

Area of Science:

• Oncology
• Immunotherapy
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard treatment for EGFR-mutated non-small cell lung cancer (NSCLC).
• Acquired resistance to third-generation TKIs necessitates novel therapeutic strategies for advanced NSCLC.

Purpose of the Study:

• To evaluate ivonescimab, a novel bispecific antibody targeting PD-1 and VEGF, in combination with chemotherapy.
• To assess the efficacy and safety of ivonescimab plus chemotherapy as a second-line treatment for patients with EGFR-mutated NSCLC after third-generation TKI failure.

Main Methods:

• The HARMONi-A trial is a clinical study investigating the efficacy of ivonescimab plus chemotherapy.
• Patient population includes individuals with EGFR-mutated NSCLC who have previously received third-generation TKIs.

Main Results:

• Recent results from the HARMONi-A trial indicate promising outcomes for the combination therapy.
• Ivonescimab, targeting both PD-1 and VEGF, demonstrates potential as a new therapeutic approach.

Conclusions:

• Ivonescimab plus chemotherapy represents a potential new second-line treatment option for EGFR-mutated NSCLC.
• This combination therapy may address unmet needs in patients progressing after standard TKI treatment.